Unlock instant, AI-driven research and patent intelligence for your innovation.

Novel crystal forms of anticancer compound CX1409 dihydrate and DMSO solvate, and preparation method and applications thereof

A technology of CX1409 and dihydrate, applied in organic chemical methods, medical preparations containing active ingredients, organic chemistry, etc., can solve problems such as poor storage, easy degradation, and restrictions on popularization and application, and achieve the effect of performance improvement

Inactive Publication Date: 2018-03-13
BEIJING KONRUNS PHARM CO LTD
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] The above-mentioned anti-cancer compound CX1409 dihydrate is known to be used for anti-cancer, but so far, there has been no related research on the crystal form, and the original CX1409 amorphous powder has the defects of poor stability, easy degradation, and poor storage, which limits its application in clinical

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel crystal forms of anticancer compound CX1409 dihydrate and DMSO solvate, and preparation method and applications thereof
  • Novel crystal forms of anticancer compound CX1409 dihydrate and DMSO solvate, and preparation method and applications thereof
  • Novel crystal forms of anticancer compound CX1409 dihydrate and DMSO solvate, and preparation method and applications thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0073] Embodiment 1: the preparation of CX1409 crude product

[0074] The preparation flow chart of CX1409 crude product is shown in the following formula:

[0075]

[0076] Specifically include the following steps:

[0077] (1) Dissolve CX1409-01 (15g) in DMF (45mL), then add imidazole (5.22g), control the temperature at about 20-25°C while stirring, slowly add TESCl (6.74g), dropwise, 20 Stir at ~25°C for 0.5h. After the reaction was complete, purified water (105 mL) and DCM (150 mL) were added to separate the layers. The organic phase was washed with water (105 mL) and saturated NaCl (75 mL). The liquid was separated, and the organic phase was evaporated to dryness to obtain the crude product. Add n-hexane (150 mL) and EA (15 mL) to the crude product, stir at room temperature for 1 h, filter with suction, wash the filter cake with a small amount of n-hexane, and vacuum-dry at 40°C for 2 h to obtain 16.7 g of the product CX1409-05.

[0078] (2) Under the protection o...

Embodiment 2

[0084] Example 2: Preparation of CX1409 dihydrate crystal form C

[0085] Weigh 1.0 g of crude CX1409 (prepared in Example 1) and add it to 5 mL of tetrahydrofuran, stir for 10 min, then add 6 mL of tetrahydrofuran, heat to 55 ° C to dissolve until clear, and keep for 45 min; slowly drop the clear solution into Stir in 9mL of 55°C water at a low speed, slowly cool down to 30°C (cooling rate is 0.5°C / min), grow crystals at constant temperature for 60 minutes, then continue to slowly cool down to 10°C (cooling rate is 0.3°C / min), grow crystals for 120 minutes The resulting crystals were collected by filtration and dried at 40° C. for 16 h under vacuum to obtain 725 mg of Form C (purity: 99.43%), whose powder X-ray diffraction pattern is shown in image 3 .

Embodiment 3

[0086] Example 3: Preparation of CX1409 dihydrate crystal form C

[0087] Weigh 1.0 g of CX1409 crude product (prepared in Example 1) and add it to 10 mL of tetrahydrofuran, heat to 50 ° C to dissolve until clear, and keep for 30 min; slowly drop the clear solution into 9 mL of 50 ° C water, stir at a low speed , slowly cool down to 25°C (cooling rate is 0.5°C / min), grow crystals at constant temperature for 40 minutes, then continue to slowly cool down to 5°C (cooling rate is 0.3°C / min), grow crystals for 90 minutes; the obtained crystals are collected by filtration, and in Drying at 40°C for 16 h under vacuum conditions yielded 786 mg of Form C (purity: 99.37%), and its powder X-ray diffraction pattern is shown in image 3 .

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
melting pointaaaaaaaaaa
melting pointaaaaaaaaaa
Login to View More

Abstract

The invention belongs to the field of compound, and more specifically relates to a novel crystal form of anticancer compound CX1409 dihydrate and a novel crystal form of DMSO solvate. Characteristic diffraction peaks of the crystal form C of anticancer compound CX1409 dihydrate can be observed at 2theta+-0.3 DEG of 5.0 DEG, 5.8 DEG, 10.4 DEG, 12.8 DEG, 13.6 DEG, 15.2 DEG, 18.6 DEG, 20.0 DEG, 20.7DEG, 21.6 DEG, 22.1 DEG, and 22.8 DEG in an X-ray powder diffraction spectrum. Characteristic diffraction peaks of the crystal form D of the DMSO solvate of the anticancer compound CX1409 can be observed at 2theta+-0.3 DEG of 8.1 DEG, 8.6 DEG, 11.1 DEG, 11.4 DEG, 12.4 DEG, 13.0 DEG, 13.8 DEG, 14.2 DEG, 14.8 DEG, 15.3 DEG, 15.8 DEG, 17.2 DEG, 18.0 DEG, 18.2 DEG, 19.7 DEG, 20.0 DEG, and 22.3 DEG inan X-ray powder diffraction spectrum. The two novel crystal forms are disclosed for the first time; the contours are clear; perfect reproduction can be realized; stability, yield, and purity are high;the novel crystal forms can be used for preparation of antitumor drugs, and the application prospect is promising.

Description

technical field [0001] The invention relates to a compound crystal, in particular to a new crystal form of an anticancer compound CX1409 dihydrate and a DMSO solvate, a preparation method and application thereof. Background technique [0002] Since the US FDC approved paclitaxel for the treatment of ovarian cancer in 1993, paclitaxel and its derivatives have been widely used in breast cancer, non-small cell lung cancer, head and neck cancer, gastric cancer, and prostate cancer. Among the current anticancer drugs, paclitaxel is a class of anticancer drugs with the widest therapeutic effect, the lowest toxicity and the highest curative effect. [0003] Currently, there are 3 paclitaxel drugs approved for use worldwide, they are paclitaxel, docetaxel and cabazitaxel. [0004] The anticancer compound CX1409 involved in the present invention has a CAS number of 125354-16-7 and a molecular formula of C 45 h 55 NO 15 , molecular weight: 849.92, easily soluble in methanol, its c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D305/14A61K31/337A61P35/00
CPCC07B2200/13C07D305/14
Inventor 姚鹏张志强殷艳松张学辉王锡娟
Owner BEIJING KONRUNS PHARM CO LTD